New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used – Part 2 of 3
If a DNA abnormality is found, a colonoscopy would still be needed to confirm the results, just as happens now after a explicit fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist’s team tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.
The examine was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this size are considered pre-cancers and most likely to progress to cancer.
The appreciativeness of the test is much better than what has been seen in other stool screening tests, the ACS’ Brooks added. “But, showing that in a small group of samples is very different from demonstrating that in a population where only a small number of individuals are going to have polyps of that size. Then we will recall if this is a big step forward”.
According to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps. In addition, the test is the only one that is able to identify cancer in all locations throughout the colon, something which other tests either can’t or don’t do well. One more advantage: patients do not call to do any special preparation before taking the test, something that other tests require.
Ahlquist noted that the test still needs to be refined. “We cultured there are still some bugs and we can make the test even better”. Cologuard is not yet available for sale. Clinical trials comparing the test with colonoscopy are slated to start next year. Ahlquist hopes that the test will be approved and on tap within two years.